PG
PCRX icon

PEAK6 Group’s Pacira BioSciences PCRX Stock Holding History

PEAK6 Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,571
Closed -$170K – 4878
2017
Q2 		$170K Buy
+3,571
New +$166K ﹤0.01% 3497
2016
Q1 		– Sell
-9,133
Closed -$534K – 4890
2015
Q4 		$701K Sell
9,133
-22,812
-71% -$1.29M ﹤0.01% 2264
2015
Q3 		$1.31M Buy
31,945
+17,930
+128% +$1.1M 0.01% 1941
2015
Q2 		$991K Buy
+14,015
New +$1.1M 0.01% 2098
2014
Q2 		– Sell
-10,534
Closed -$737K – 5003
2014
Q1 		$737K Buy
+10,534
New +$716K 0.01% 2148
2013
Q4 		– Sell
-24,668
Closed -$1.19M – 5313
2013
Q3 		$1.19M Buy
+24,668
New +$899K 0.01% 2007

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

PEAK6 Group's PCRX Position: Q3 2017 in Review

PEAK6 Group sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 3,571 shares — an estimated $170K sold.

PEAK6 Group first reported a position in PCRX in Q3 2013 and held it in 6 quarters. The position peaked at $1.31M in Q3 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

  • PEAK6 Group reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
  • PEAK6 Group sold 3,571 Pacira BioSciences shares in Q3 2017, an estimated $170K.
  • PEAK6 Group first reported a position in Pacira BioSciences in Q3 2013 and held it in 6 quarters.
  • PEAK6 Group's Pacira BioSciences position peaked at $1.31M in Q3 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on PEAK6 Group's 13F filing for Q3 2017, filed 14 Nov 2017.